CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• KRAS G12C mutations occur in 14% of lung adenocarcinoma, particularly in smokers.
• Targeting KRAS G12C was historically challenging due to protein structure and rapid GTP hydrolysis.
• Sotorasib is the first-in-class covalent inhibitor targeting the KRAS G12C-GDP 'off' state.

Purpose of the Study:

• To evaluate the efficacy and clinical impact of sotorasib in KRAS G12C-mutated non-small cell lung cancer (NSCLC).
• To discuss the significance of sotorasib's approval and clinical trial results in the context of targeted cancer therapy.

Main Methods:

• Analysis of Phase II CodeBreaK 100 trial data for sotorasib in KRAS G12C+ NSCLC.
• Comparison of sotorasib's progression-free survival (PFS) against docetaxel at the European Society of Medical Oncology (ESMO) 2022 annual meeting.

Main Results:

• Sotorasib demonstrated an objective response rate (ORR) of 36% and median response duration of 10 months in 124 patients.
• Sotorasib showed a statistically significant improvement in PFS over docetaxel (HR=0.66, P=0.002), extending PFS by 1.1 months.
• The ORR was 28% in the comparative analysis, prompting debate on clinical significance.

Conclusions:

• Sotorasib represents a significant advancement in targeted therapy for KRAS G12C-mutated NSCLC.
• Despite modest PFS gains, sotorasib's approval and efficacy data support its classification as a breakthrough treatment.
• Further research and debate are warranted to fully understand sotorasib's long-term impact and optimal use.